Panthea
Panthea develops precision microbiome support for women navigating perimenopause and menopause, targeting the gut-brain-nervous system connection rather than individual symptoms. Its flagship product, Panthea Core, is a patent-pending, non-hormonal probiotic strain backed by 38 published papers and a clinical trial scheduled for 2026. The company is currently building a waitlist of early adopters with founding member pricing.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Consumer Goods
Funding
Founders
Founder details are not available yet.
Product
Problem
Women in the menopause transition often experience disruptive symptoms like sleep disturbances, mood swings, energy crashes, and temperature dysregulation. These symptoms are frequently treated in isolation, despite growing research pointing to weakened gut-brain communication via the vagus nerve as a key biological driver. Existing products rarely target this underlying mechanism.
Solution
Panthea provides precision microbiome support designed specifically for the menopause transition, targeting the gut-brain axis to support nervous system signaling. Its flagship product, Panthea Core, is a patent-pending probiotic strain developed from over fifteen years of federally funded research, including 38 published papers. The formulation is non-hormonal by design and aims to address the biology behind symptoms rather than just masking them. A clinical trial is scheduled to launch in 2026, and the company offers community events, webinars, and research updates to educate and engage its audience.
Target Audience
Panthea's primary customers are women in the 38-65 demographic experiencing perimenopause or menopause who are seeking science-backed, non-hormonal solutions for sleep, mood, energy, and temperature regulation challenges.
Features
- Patent-pending probiotic strain developed from more than 15 years of federally funded university research, with 38 published papers
- Formulation specifically designed for women ages 38-65 navigating perimenopause and menopause
- Targets the gut-brain-nervous system connection, supporting the vagus nerve and nervous system signaling
- Non-hormonal approach, offering an alternative for women seeking non-hormonal symptom management
- Clinical trial designed alongside the formulation, launching in 2026, with research grounded and published in academic journals
- Waitlist program with founding member pricing, early access, webinars, and monthly research updates